Therapeutic Peptide Programs
Chronic diseases across listed specialties (e.g., Endocrinology, Cardiology)
Approved/Expanded AccessActive
Key Facts
Indication
Chronic diseases across listed specialties (e.g., Endocrinology, Cardiology)
Phase
Approved/Expanded Access
Status
Active
Company
About 1Elevan Bio
1Elevan Bio is a private, pre-revenue biotech firm founded in 2021, developing and delivering peptide-based therapeutics. The company's strategy centers on utilizing existing FDA-approved peptides and pursuing expanded access pathways to address chronic diseases across multiple specialties including endocrinology, cardiology, and oncology. With operations launching in Spring 2026, 1Elevan is positioning itself at the intersection of advanced peptide science and patient-centric therapeutic delivery, aiming to shift treatment paradigms away from traditional small-molecule drugs.
View full company profile